CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Growth Stocks: Boston Scientific Corp.

13:57 1 June 2021

Boston Scientific Corporation (BSX.US), operating as Boston Scientific, is a manufacturer of interventional medical devices used in medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, surgery cardiac, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is best known for the development of the Taxus Stent, a drug-eluting stent used to open clogged arteries.

Although Boston Scientific Corporation was founded in 1979, its activity linked to medicine and the development of recognition machinery as well as various surgical modalities, constitute it as one of the worldwide references that annually increases your income. Being a mature company that can be considered valuable in the stock market, investors already have a growth projection and based on that parameter we are going to analyze the company.

Start investing today or test a free demo

Open account Try demo Download mobile app Download mobile app

Earnings

One of the worst quarters that the company has published its results was the second quarter of 2020 with turnover levels equivalent to the last quarter of 2016, however an exception to the Q3 of 2020 returned to recover levels even above the same periods from the previous year. In its last publication of results for Q1 2021. Its turnover reached 2,752 million dollars, surpassing the mark of the same quarter of 2020 of 2,543 million dollars.

source: macrotrends

The resilience that Boston Scientific Corp has shown during the last quarters in which it has recovered the billing levels prior to the impact of the coronavirus shows the capacity and volume of business generated in the medical field.

Regarding its EPS, the company returns to recover levels prior to the impact of the pandemic and in its last publication of Q1 2021 showed an EPS of $ 0.23 levels close to the $ 0.30 published in Q1 2019.

source: macrotrends

Constant Innovation

One of the fundamental aspects in the success of the evolution of its income is the constant evolution in its research and development (R&D) department. With certain recurrence the company attends technological innovation congresses in the medical field and always attends with news of both new machinery and updates or improvements to existing ones.

For example, one of their latest developments published on May 25, has been to obtain European certification for a single-use bronchoscope, designed for bedside procedures in the intensive care unit, I want an operating room and a bronchoscopy room, where do they hope to launch it? to the European market in the coming weeks.

Also in the American market are pending FDA approval of glass microspheres with the name TheraSphere Y-90 to combat and treat patients with hepatocellular carcinoma. According to the description, the approval will expand access to a therapy that prolongs life for a greater number of patients than to date, had only been used under a humanitarian device exemption.

Hepatocellular carcinoma or HCC, is one of the most prevalent cancers in the world and the most common type of primary liver cancer, annually more than 500,000 new cases are diagnosed worldwide and it is treated by surgery, liver transplantation, chemotherapy or embolization. The TheraSphere Y-90 treatment aims through the glass microspheres containing radioactive yttrium, to treat liver tumors directly with a catheter reducing the invasion exposure of the surrounding healthy tissue.

Technical analysis

The company has been developing an upward trend since 2012 where its historical lows match at $ 4.79, Boston Scientific has had a parabolic behavior where its historical maximum of 2004 was retested just before the impact of the pandemic.

source: xStation

Since the March lows, the fall has still not been fully recovered, but taking into account that the highs prior to the decline are historical highs, a break in these levels would mark unexplored terrain that should surpass strongly.

 

Darío García
XTB Spain

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Back
Xtb logo

Join over 1 Million investors from around the world

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 17 October 2024
adobe_unique_id cc 16 October 2025
test_cookie cc 1 March 2024
SESSID cc 9 September 2022
__hssc cc 16 October 2024
__cf_bm cc 16 October 2024
intercom-id-iojaybix cc 13 July 2025
intercom-session-iojaybix cc 23 October 2024
xtbCookiesSettings cc 16 October 2025
xtbLanguageSettings cc 16 October 2025
TS5b68a4e1027
countryIsoCode
userPreviousBranchSymbol cc 16 October 2025
TS5b68a4e1027
_cfuvid
intercom-device-id-iojaybix cc 13 July 2025
__cfruid
__cf_bm cc 16 October 2024
__cf_bm cc 16 October 2024
_cfuvid
adobe_unique_id cc 16 October 2025
TS5b68a4e1027
_cfuvid
xtbCookiesSettings cc 16 October 2025
SERVERID
TS5b68a4e1027
__hssc cc 16 October 2024
test_cookie cc 1 March 2024
intercom-id-iojaybix cc 13 July 2025
intercom-session-iojaybix cc 23 October 2024
intercom-device-id-iojaybix cc 13 July 2025
UserMatchHistory cc 31 March 2024
__cf_bm cc 16 October 2024
__cf_bm cc 16 October 2024
__cf_bm cc 16 October 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
_gid cc 9 September 2022
_gat_UA-22576382-1 cc 8 September 2022
_gat_UA-121192761-1 cc 8 September 2022
_ga_CBPL72L2EC cc 16 October 2026
_ga cc 16 October 2026
AnalyticsSyncHistory cc 8 October 2022
af_id cc 31 March 2025
afUserId cc 1 March 2026
af_id cc 1 March 2026
AF_SYNC cc 8 March 2024
__hstc cc 14 April 2025
__hssrc
_vwo_uuid_v2 cc 17 October 2025
_ga_TC79BEJ20L cc 16 October 2026
_vwo_uuid cc 16 October 2025
_vwo_ds cc 15 November 2024
_vwo_sn cc 16 October 2024
_vis_opt_s cc 24 January 2025
_vis_opt_test_cookie
_ga cc 16 October 2026
_ga_CBPL72L2EC cc 16 October 2026
__hstc cc 14 April 2025
__hssrc
_ga_TC79BEJ20L cc 16 October 2026
af_id cc 31 March 2025
afUserId cc 1 March 2026
af_id cc 1 March 2026
AF_SYNC cc 8 March 2024
_gcl_au cc 14 January 2025
AnalyticsSyncHistory cc 31 March 2024
_gcl_au cc 14 January 2025

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
MUID cc 10 November 2025
_omappvp cc 28 September 2035
_omappvs cc 16 October 2024
_uetsid cc 17 October 2024
_uetvid cc 10 November 2025
_fbp cc 14 January 2025
fr cc 7 December 2022
muc_ads cc 16 October 2026
lang
_ttp cc 10 November 2025
_tt_enable_cookie cc 10 November 2025
_ttp cc 10 November 2025
hubspotutk cc 14 April 2025
YSC
VISITOR_INFO1_LIVE cc 14 April 2025
hubspotutk cc 14 April 2025
_uetsid cc 17 October 2024
_uetvid cc 10 November 2025
_ttp cc 10 November 2025
MUID cc 10 November 2025
_fbp cc 14 January 2025
_tt_enable_cookie cc 10 November 2025
_ttp cc 10 November 2025
li_sugr cc 30 May 2024
guest_id_marketing cc 16 October 2026
guest_id_ads cc 16 October 2026
guest_id cc 16 October 2026
MSPTC cc 10 November 2025
IDE cc 10 November 2025
VISITOR_PRIVACY_METADATA cc 14 April 2025
guest_id_marketing cc 16 October 2026
guest_id_ads cc 16 October 2026
guest_id cc 16 October 2026
muc_ads cc 16 October 2026
MSPTC cc 10 November 2025
IDE cc 10 November 2025

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description
personalization_id cc 16 October 2026
UserMatchHistory cc 8 October 2022
bcookie cc 16 October 2025
lidc cc 17 October 2024
lang
bscookie cc 8 September 2023
li_gc cc 14 April 2025
bcookie cc 16 October 2025
lidc cc 17 October 2024
bscookie cc 1 March 2025
li_gc cc 14 April 2025
personalization_id cc 16 October 2026

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language